
A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India's largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries'.
この企業が各市場へ参入した順序 — 古い順から新しい順へ
登録してシグナルフィードをすべて表示
Alkem Laboratories Ltd. の海外展開を競合と比較
バーは比較対象企業間の相対的な規模を示します。
列5| 企業 | 市場 | 新規市場 | モメンタム | アクティビティ | 拡大スコア |
|---|---|---|---|---|---|
Alkem Laboratories Ltd.自社 | 0 | 0 | 0% | 0 | 32 |
Assistant Manager - Admin/Facility Management
求人を見るMumbai, Maharashtra, India · 3日前
Human Resource Business Partner
求人を見るMumbai, Maharashtra, India · 先週
Product Manager - International Business
求人を見るNavi Mumbai, Maharashtra, India · 先週
実施中のキャンペーンはありません
この企業をフォローして、変化があり次第通知を受け取るにはサインアップしてください。
インド医薬品市場は11月に前年比9.9%成長。新製品発売と価格上昇が主な要因。ほとんどの治療分野で健全な成長を示し、皮膚科が15.8%で最高。
注目株にはタタパワー、ルピン、RVNL、NLCインディア、ICICIプルデンシャルライフ、アルケムラボが含まれます。タタパワーは利益増加を報告し、ルピンは後発HIV薬のFDA承認状況を明確にしました。
2025年2月7日、LIC、NHPC、Ola Electric、Mazagon Dock、Delhivery、M&Mを含む230社以上が第3四半期決算を発表する予定。
認証済みメールと直通電話を解放
無料 · カード不要
Alkem Laboratories Ltd. の事業、市場、成長シグナルに関する簡潔な回答。

© 2026 Pubrio. 無断転載を禁じます。